Form 4: Neurocrine Biosciences Director William Rastetter Executes Option and Sells Shares Under 10b5-1 Plan

Director William Rastetter exercised stock options and sold 30,000 shares of Neurocrine Biosciences under a pre-arranged 10b5-1 trading plan.

Summary

• On May 5, 2025, William Rastetter, a director of Neurocrine Biosciences, exercised non-qualified stock options to acquire 30,000 shares of common stock at a price of $42.76 per share.
• Simultaneously, Rastetter sold 30,000 shares of Neurocrine Biosciences common stock at a weighted average price of $110.1984 per share, with individual sales prices ranging from $108.13 to $111.16.
• The sale was executed under a Rule 10b5-1 trading plan adopted on June 14, 2024.
• Following these transactions, Rastetter directly owns 37,491 shares.
• An additional 37,491 shares are held by the Rastetter Family Trust, for which Rastetter has voting and investment power.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of insider trading activity. The director exercised options and sold shares under a pre-arranged plan, which is a common practice. There's no indication of positive or negative sentiment towards the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. Directors often use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information. The filing itself doesn't provide specific insight into Neurocrine's performance or strategy, but it does indicate how one of the company's directors is managing their personal investment in the company.

Comparison to Industry Standards

• Rule 10b5-1 trading plans are a common practice among corporate executives and directors at publicly traded companies, including those in the biotechnology sector like Amgen (AMGN), Biogen (BIIB), and Gilead Sciences (GILD).
• These plans allow insiders to sell shares in a predetermined manner, mitigating concerns about trading on non-public information.
• The specific details of the plan, such as the timing and volume of sales, are determined in advance and are not subject to the insider's discretion once the plan is in place.
• The weighted average sales price of $110.1984 per share reflects the market valuation of Neurocrine Biosciences at the time of the transaction, which can be compared to the valuation multiples (e.g., price-to-earnings ratio, price-to-sales ratio) of its peers in the biotechnology industry.

Key Dates

Keywords

Neurocrine Biosciences, NBIX, William Rastetter, Form 4, Stock Options, 10b5-1 Trading Plan, Insider Trading, Share Sale, Director, Beneficial Ownership